WAM
DRNA

Wealthspire Advisors (Maryland)’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200
Closed -$2K – 2639
2018
Q4 		$2K Hold
200
– – ﹤0.01% 2174
2018
Q3 		$3K Hold
200
– – ﹤0.01% 2098
2018
Q2 		$2K Hold
200
– – ﹤0.01% 2231
2018
Q1 		$2K Hold
200
– – ﹤0.01% 2247
2017
Q4 		$2K Hold
200
– – ﹤0.01% 2204
2017
Q3 		$1K Buy
+200
New +$728 ﹤0.01% 2178

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s DRNA Position: Q1 2019 in Review

Wealthspire Advisors (Maryland) sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2019, closing a stake of 200 shares — an estimated $2K sold.

Wealthspire Advisors (Maryland) first reported a position in DRNA in Q3 2017 and held it in 6 quarters. The position peaked at $3K in Q3 2018. 98 funds tracked by Wall St. Rank hold DRNA as of Q1 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 200 Dicerna Pharmaceuticals, Inc. shares in Q1 2019, an estimated $2K.
  • Wealthspire Advisors (Maryland) first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2017 and held it in 6 quarters.
  • Wealthspire Advisors (Maryland)'s Dicerna Pharmaceuticals, Inc. position peaked at $3K in Q3 2018.
  • 98 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q1 2019, filed 13 May 2019.